Zobrazeno 1 - 10
of 423
pro vyhledávání: '"Maurizio, Scaltriti"'
Publikováno v:
Molecular Oncology, Vol 18, Iss 11, Pp 2607-2611 (2024)
The incorporation of novel therapeutic agents such as antibody‐drug conjugates, radio‐conjugates, T‐cell engagers, and chimeric antigen receptor cell therapies represents a paradigm shift in oncology. Cell‐surface target quantification, quant
Externí odkaz:
https://doaj.org/article/9d347ab686e440cd84951119568cca8f
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltriti
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gen
Externí odkaz:
https://doaj.org/article/5085bbfc4563442588c40da205b8c222
Autor:
Daniele Generali, Giancarlo Bosio, Fabio Malberti, Antonio Cuzzoli, Sophie Testa, Laura Romanini, Antonio Fioravanti, Alessandro Morandini, Luca Pianta, Guglielmo Giannotti, Erika Maria Viola, Matteo Giorgi-Pierfranceschi, Marina Foramitti, Rosa Angela Tira, Ilaria Zangrandi, Giulia Chiodelli, Andrea Machiavelli, Maria Rosa Cappelletti, Alessia Giossi, Valeria De Giuli, Chiara Costanzi, Chiara Campana, Ottavia Bernocchi, Marianna Sirico, Alessia Zoncada, Alfredo Molteni, Sergio Venturini, Fabiola Giudici, Maurizio Scaltriti, Angelo Pan
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss , Pp 433-440 (2021)
Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. Design: This study aimed to evaluate the reduction
Externí odkaz:
https://doaj.org/article/43321c41d17e4354b37611a7055eca43
Autor:
Konstantinos V. Floros, Sheeba Jacob, Richard Kurupi, Carter K. Fairchild, Bin Hu, Madhavi Puchalapalli, Jennifer E. Koblinski, Mikhail G. Dozmorov, Sosipatros A. Boikos, Maurizio Scaltriti, Anthony C. Faber
Publikováno v:
Cell Death and Disease, Vol 12, Iss 2, Pp 1-13 (2021)
Abstract Human epidermal growth factor receptor 2 gene (HER2) is focally amplified in approximately 20% of breast cancers. HER2 inhibitors alone are not effective, and sensitizing agents will be necessary to move away from a reliance on heavily toxic
Externí odkaz:
https://doaj.org/article/38b772c2e3b047a0a0603783709c7fe0
Autor:
Barak Rotblat, Andreas Mock, Jerome Fayette, Limor Cohen, Idan Cohen, Elena Voronov, Jebrane Bouaoud, Lucas Michon, Pierre Saintigny, Luc G T Morris, Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Ofra Novoplansky, Mai Badarni, Ksenia M Yegodayev, Sapir Tzadok, Libor Brezina, Andy Karabajakian, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Moshe Elkabets
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed to characterize the effect o
Externí odkaz:
https://doaj.org/article/e52b0f83da384bc987314eeb1cc6f2e4
Autor:
Lidia Mateo, Miquel Duran-Frigola, Albert Gris-Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi, Sarat Chandarlapaty, Joaquin Arribas, Meritxell Bellet, Violeta Serra, Patrick Aloy
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-23 (2020)
Abstract Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) network
Externí odkaz:
https://doaj.org/article/8d63f66e5204442188fe04baf4456244
Autor:
Kwanghee Kim, Wenhuo Hu, François Audenet, Nima Almassi, Aphrothiti J. Hanrahan, Katie Murray, Aditya Bagrodia, Nathan Wong, Timothy N. Clinton, Shawn Dason, Vishnu Mohan, Sylvia Jebiwott, Karan Nagar, Jianjiong Gao, Alex Penson, Chris Hughes, Benjamin Gordon, Ziyu Chen, Yiyu Dong, Philip A. Watson, Ricardo Alvim, Arijh Elzein, Sizhi P. Gao, Emiliano Cocco, Alessandro D. Santin, Irina Ostrovnaya, James J. Hsieh, Irit Sagi, Eugene J. Pietzak, A. Ari Hakimi, Jonathan E. Rosenberg, Gopa Iyer, Herbert A. Vargas, Maurizio Scaltriti, Hikmat Al-Ahmadie, David B. Solit, Jonathan A. Coleman
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
The advancement of upper tract urothelial carcinoma (UTUC) research is hampered by the lack of disease-specific models. Here, the authors report patient derived xenograft and cell line models of UTUC, and show that these models retain the genomic and
Externí odkaz:
https://doaj.org/article/21deaeb5b9144f9aa0be74b0bca108b3
Autor:
Sonia Pernas, Patricia Villagrasa, Ana Vivancos, Maurizio Scaltriti, Jordi Rodón, Octavio Burgués, Paolo Nuciforo, Jordi Canes, Laia Paré, Marta Dueñas, Maria Vidal, Juan Miguel Cejalvo, Antonia Perelló, Antonio Llommbard-Cussac, Joan Dorca, Alvaro Montaño, Tomás Pascual, Mafalda Oliveira, Gloria Ribas, Inmaculada Rapado, Aleix Prat, Eva Ciruelos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThe SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targete
Externí odkaz:
https://doaj.org/article/bc3ebc5d1a36401a91652476aa999c1a